The most common side effects reported by more than 2% of clinical trials subjects are hypercalciuria, dizziness, nausea, headache, palpitations, fatigue, upper abdominal pain and vertigo. Preclinical studies revealed that<unk>  systemic daily administration leads to a dose- and time-dependent increase in the incidence of osteosarcoma in rodents. However, whether<unk> -SC will cause osteosarcoma in humans is unknown. Thus, the use of<unk>  is not recommended for individuals at increased risk of osteosarcoma. Additionally, its use is not advised for more than 2 years during a patient's lifetime.
Abaloparatide
Liranaftate
Insulin degludec
Ultralente insulin
Voglibose
Lente insulin
Regular insulin
Edotreotide